Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib Plus Rituximab vs Cladribine in Front-line Hairy Cell Leukemia
2024-520119-41-00Phase 2Authorised
- Sponsor
- University of Perugia
- Start
- Jan 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in hairy cell leukemia (HCL) comparing Cladribine ± Sequential Rituximab with Vemurafenib Plus Rituximab (2 arms). Primary endpoints: Complete remission rate at ~6 months and Incidence of grade ≥3 drug-related toxicity within 6 months. Planned start Jan 2025; status: authorised.
02
Drugs
vemurafenibrituximabcladribine
03
Conditions
hairy cell leukemia (HCL)
Beyond the preview
Go deeper on 2024-520119-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520119-41-00.